<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04994093</url>
  </required_header>
  <id_info>
    <org_study_id>TCRact</org_study_id>
    <secondary_id>POIR.01.01.01-00-0019/20</secondary_id>
    <nct_id>NCT04994093</nct_id>
  </id_info>
  <brief_title>Creating an Innovative AI-based TCRact to Launch a NEW SERVICE for Designing and Optimizing T-cell Receptors (TCR) for Use in Cancer Immunotherapies</brief_title>
  <official_title>Creating an Innovative AI-based (Artificial Intelligence) IN SILICO TECHNOLOGY TCRact to Launch a NEW SERVICE for Designing and Optimizing T-cell Receptors (TCR) for Use in Cancer Immunotherapies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ardigen</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Center for Research and Development, Poland</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Ardigen</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The PROJECT OBJECTIVE is to create an innovative AI-based (Artificial Intelligence) IN SILICO&#xD;
      TECHNOLOGY for the design and optimization of T-cell receptors (TCRs) capable of recognizing&#xD;
      specific tumor antigens presented on Human Leukocyte Antigen (HLA). The technology will be&#xD;
      based on bioinformatics (including molecular modelling) and artificial intelligence&#xD;
      (including predictive, generative and optimization models). PROJECT TASKS are dedicated to&#xD;
      the implementation of individual technological components (including the database necessary&#xD;
      for their preparation) and to performing IN VITRO evaluation rounds to optimize the&#xD;
      technology.&#xD;
&#xD;
      Integration, within an IN SILICO TECHNOLOGY, of processes which currently require huge&#xD;
      amounts of in vitro laboratory experiments that are necessary for bringing new TCR-based&#xD;
      cancer immunotherapies into clinical trials:&#xD;
&#xD;
        -  finding appropriate TCRs targeting cancer neoantigen presented on a HLA molecule (pHLA)&#xD;
&#xD;
        -  testing for potential TCR toxicity (targeting self antigens presented on healthy&#xD;
           tissues)&#xD;
&#xD;
        -  optimization of pHLA:TCR binding affinity and toxicity.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 2021</start_date>
  <completion_date type="Anticipated">January 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Finding appropriate TCRs targeting cancer neoantigen presented on a HLA molecule (pHLA)</measure>
    <time_frame>Inclusion</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Testing for potential TCR toxicity (targeting self antigens presented on healthy tissues)</measure>
    <time_frame>Inclusion</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Optimization of pHLA:TCR binding affinity and toxicity</measure>
    <time_frame>Inclusion</time_frame>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Colon Cancer</condition>
  <condition>Cancer</condition>
  <arm_group>
    <arm_group_label>COLON CANCER</arm_group_label>
    <description>This cohort will consist of 100 patients with Colon Cancer.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Collection of blood (PBMC), biopsy (FFPE) and stool samples.</intervention_name>
    <description>Patients receiving routine treatment financed by the Polish National Health Fund (NFZ).</description>
    <arm_group_label>COLON CANCER</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      stool, biopsy (FFPE) and peripheral blood samples (PBMC)&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients receiving routine treatment.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Clinical diagnosis of advanced resectable colorectal cancer (Active stage III or IV)&#xD;
&#xD;
          -  Histopathologically confirmed as adenocarcinoma&#xD;
&#xD;
          -  Age 18 or over&#xD;
&#xD;
          -  Being able to understand and sign the Informed Consent Form (ICF)&#xD;
&#xD;
          -  Qualification for resection within 3 months from W0 or condition after primary tumor&#xD;
             resection, not longer than 5 years from surgery&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Mucinous colorectal adenocarcinoma&#xD;
&#xD;
          -  Canal and anal edge cancer,&#xD;
&#xD;
          -  Adenocarcinoma of the appendix,&#xD;
&#xD;
          -  Patients treated with neoadjuvant therapy or radiation therapy in the 3 months prior&#xD;
             to study enrollment.&#xD;
&#xD;
          -  Patients treated with systemic chemotherapy in the 3 months prior to study enrollment.&#xD;
&#xD;
          -  Histopathological diagnosis other than adenocarcinoma&#xD;
&#xD;
          -  Remission&#xD;
&#xD;
          -  History of inflammatory bowel diseases&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  HIV infection&#xD;
&#xD;
          -  Active infection with hepatitis B and C viruses&#xD;
&#xD;
          -  Leukocytopenia&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Martyna Balawejder</last_name>
    <phone>+48 883 319 890</phone>
    <email>martyna.balawejder@ardigen.com</email>
  </overall_contact>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>July 29, 2021</study_first_submitted>
  <study_first_submitted_qc>August 5, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 6, 2021</study_first_posted>
  <last_update_submitted>August 5, 2021</last_update_submitted>
  <last_update_submitted_qc>August 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 6, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Immunology</keyword>
  <keyword>TCR</keyword>
  <keyword>FFPE</keyword>
  <keyword>PBMC</keyword>
  <keyword>Colon Cancer</keyword>
  <keyword>Immuno-Oncology</keyword>
  <keyword>Cancer</keyword>
  <keyword>Oncology</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colonic Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

